Literature DB >> 9015017

Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms.

P J Sulak1, B E Cressman, E Waldrop, S Holleman, T J Kuehl.   

Abstract

OBJECTIVE: To test the hypothesis that extending the number of consecutive active oral contraceptives (OC)s given will decrease the frequency of menstrual-related problems including dysmenorrhea, menorrhagia, premenstrual-type symptoms, and menstrual migraines.
METHODS: A prospective analysis was designed to track the experiences of 50 women taking OCs and experiencing menstrual-related problems. Fifty consecutive patients, who were taking OCs and had symptoms during the pill-free interval, were followed in a multispecialty clinic by an individual physician and nurse practitioner team. The patients were permitted to extend the number of consecutive active OCs to delay menstrual-related symptoms.
RESULTS: Immediate outcome of the 50 patients revealed 74% (37 patients) stabilized on an extended regimen of 6 to 12 weeks of consecutive days with active OCs. Twenty-six percent (13 patients) either discontinued OCs or returned to the standard regimen with 3 weeks of active pills. Of the 37 patients who were stabilized on an extended regimen, 27 have completed thus far between five and 13 extended cycles with 6-23 months of follow-up (mean 16 months).
CONCLUSIONS: Experience in a series of 50 OC users with menstrual-related symptoms demonstrated that delaying menses by extending the number of consecutive days of active pills is well tolerated and efficacious. We believe that a large prospective study is warranted to further our knowledge in this area.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9015017     DOI: 10.1016/S0029-7844(96)00488-7

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  15 in total

Review 1.  Noncontraceptive health benefits of oral contraceptives.

Authors:  Andrew M Kaunitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

2.  Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow
Journal:  Depress Anxiety       Date:  2017-07-17       Impact factor: 6.505

Review 3.  A contemporary approach to dysmenorrhea in adolescents.

Authors:  Zeev Harel
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Prevention and treatment of menstrual migraine.

Authors:  E Anne MacGregor
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

Review 5.  The use of triptans in the management of menstrual migraine.

Authors:  Lisa K Mannix; Julia A Files
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 6.  Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): A Review of Its Use as an Oral Contraceptive.

Authors:  Celeste B Burness
Journal:  Drugs       Date:  2015-06       Impact factor: 9.546

Review 7.  Long-cycle treatment with oral contraceptives.

Authors:  Inka Wiegratz; Herbert Kuhl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Endometriosis: current therapies and new pharmacological developments.

Authors:  Paolo Vercellini; Edgardo Somigliana; Paola Viganò; Annalisa Abbiati; Giussy Barbara; Pier Giorgio Crosignani
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception.

Authors:  Alison Edelman; Elizabeth Micks; Maria F Gallo; Jeffrey T Jensen; David A Grimes
Journal:  Cochrane Database Syst Rev       Date:  2014-07-29

10.  New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control.

Authors:  Anita Nelson
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.